Stockhead feature article
This comprehensive feature explores Cynata's transition from early-stage to late-stage clinical biotech. CEO Dr Kilian Kelly discusses how our proprietary Cymerus™ platform overcomes the major manufacturing limitations that have held back conventional MSC therapies, and why 2026 represents a potentially transformative period for the Company.
Read the article: https://www.theaustralian.com.au/business/stockhead/news/cynata-positioned-for-2026-trial-readouts-after-doing-the-leg-work-in-2025/news-story/ad4a2700f9fd6558a8ce13b7d1c4f79d
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Cynata Therapeutics. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Cynata Therapeutics a question about this update.